TD Asset Management Inc Sells 65,000 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Key Points

• TD Asset Management Inc reduced its stake in Celldex Therapeutics by 45.2%, selling 65,000 shares and holding 78,878 shares valued at $1.43 million post-sale.
• Celldex Therapeutics reported a quarterly loss with an EPS of ($0.81), missing estimates, and a revenue of $0.70 million against analyst expectations of $1.08 million.
• The stock currently holds a consensus rating of "Moderate Buy" from analysts, with varying price targets ranging from $31.00 to $64.00.

TD Asset Management Inc lessened its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 45.2% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 78,878 shares of the biopharmaceutical company's stock after selling 65,000 shares during the period. TD Asset Management Inc owned 0.12% of Celldex Therapeutics worth $1,432,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the business. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Celldex Therapeutics in the 1st quarter valued at about $269,000. Values First Advisors Inc. grew its position in shares of Celldex Therapeutics by 3.2% in the first quarter. Values First Advisors Inc. now owns 29,933 shares of the biopharmaceutical company's stock valued at $550,000 after purchasing an additional 924 shares during the last quarter. SG Americas Securities LLC increased its stake in shares of Celldex Therapeutics by 38.0% during the first quarter. SG Americas Securities LLC now owns 34,884 shares of the biopharmaceutical company's stock worth $633,000 after purchasing an additional 9,601 shares during the period. Apella Capital LLC bought a new position in shares of Celldex Therapeutics during the first quarter worth approximately $309,000. Finally, Mirador Capital Partners LP lifted its holdings in Celldex Therapeutics by 7.0% during the 1st quarter. Mirador Capital Partners LP now owns 127,874 shares of the biopharmaceutical company's stock worth $2,321,000 after purchasing an additional 8,382 shares during the last quarter.

Celldex Therapeutics Stock Up 1.0%

Shares of Celldex Therapeutics stock opened at $22.19 on Monday. Celldex Therapeutics, Inc. has a 12-month low of $14.40 and a 12-month high of $47.00. The company has a market capitalization of $1.47 billion, a price-to-earnings ratio of -8.22 and a beta of 1.22. The firm's 50-day moving average price is $21.36 and its two-hundred day moving average price is $20.79.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). The firm had revenue of $0.70 million for the quarter, compared to analyst estimates of $1.08 million. Celldex Therapeutics had a negative return on equity of 23.46% and a negative net margin of 2,366.07%. On average, sell-side analysts expect that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have commented on the company. UBS Group decreased their price objective on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Morgan Stanley decreased their price target on shares of Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating on the stock in a research note on Friday, May 9th. The Goldman Sachs Group lowered their price target on shares of Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating on the stock in a research report on Friday, May 9th. Canaccord Genuity Group began coverage on shares of Celldex Therapeutics in a research note on Monday, April 28th. They issued a "buy" rating and a $64.00 price objective for the company. Finally, HC Wainwright restated a "buy" rating and set a $50.00 target price on shares of Celldex Therapeutics in a research report on Friday, June 13th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $50.11.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.

Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.